Corcept Therapeutics Inc
relacorilant
platinum-resistant ovarian cancer
Resolved
41days ago
FDA decision · Jul 11, 2026
What's at stake
The FDA's approval decision on relacorilant for platinum-resistant ovarian cancer is due Jul 11, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 2mo ago
“Corcept expects the resubmission to receive a six-month review.”